Search results

Skip to results

Type

Type

Last updated

Last updated

Guidance programme

Showing 1 result for ta597

  1. Dapagliflozin with insulin for treating type 1 diabetes (TA597)

    In November 2021, we withdrew this guidance because dapagliflozin (Forxiga) with insulin is no longer licensed for treating type 1 diabetes.